ethyl 3-bromo-4-methyl-1-benzo[b]thiophene-2-carboxylate | 1402144-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: ethyl 3-bromo-4-methyl-1-benzo[b]thiophene-2-carboxylate
• 英文别名: ethyl 3-bromo-4-methylbenzo[b]thiophene-2-carboxylate；Ethyl 3-bromo-4-methyl-benzo[b]thiophene-2-carboxylate；ethyl 3-bromo-4-methyl-1-benzothiophene-2-carboxylate
• CAS: 1402144-44-8
• 化学式: C₁₂H₁₁BrO₂S
• 分子量: 299.188
• InChiKey: RPVIZAOITLSXPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-bromo-4-methyl-1-benzo[b]thiophene-2-carboxylate 在 manganese(IV) oxide 、 硫酸 、 potassium hydroxide 、 zinc(II) iodide 作用下， 以 甲醇 、 氯化亚砜 、 二氯甲烷 、 水 为溶剂， 反应 12.5h， 生成 methyl (3-bromo-4-methyl-benzo[b]thiophen-2-yl)-hydroxy-acetate
  参考文献：
  名称：

  [EN] INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES
  [FR] INHIBITEURS DE RÉPLICATION VIRALE, LEUR PROCÉDÉ DE SYNTHÈSE ET LEURS APPLICATIONS THÉRAPEUTIQUES

  摘要：

  本发明涉及权利要求1中所述的式(1)化合物，及其用于治疗或预防病毒疾病，包括HIV。

  公开号：

  WO2012137181A1
• 作为产物：
  描述：

  2-氯-6-甲基苄腈 在 亚硝酸特丁酯 、 sodium hydride 、 copper(ll) bromide 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 、 mineral oil 为溶剂， 反应 4.25h， 生成 ethyl 3-bromo-4-methyl-1-benzo[b]thiophene-2-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES
  [FR] INHIBITEURS DE RÉPLICATION VIRALE, LEUR PROCÉDÉ DE SYNTHÈSE ET LEURS APPLICATIONS THÉRAPEUTIQUES

  摘要：

  本发明涉及权利要求1中所述的式(1)化合物，及其用于治疗或预防病毒疾病，包括HIV。

  公开号：

  WO2012137181A1

文献信息

• INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES
  申请人：Chasset Sophie

  公开号：US20140128383A1

  公开（公告）日：2014-05-08

  The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

  本发明涉及化合物及其在治疗或预防病毒性疾病，包括HIV方面的应用。
• Inhibitors of viral replication, their process of preparation and their therapeutical uses
  申请人：Chasset Sophie

  公开号：US09238026B2

  公开（公告）日：2016-01-19

  The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

  本发明涉及化合物及其在治疗或预防病毒性疾病，包括HIV方面的应用。
• Synthesis and Biological Evaluation of 2-(Alkoxycarbonyl)-3-Anilinobenzo[<i>b</i>]thiophenes and Thieno[2,3-<i>b</i>]pyridines as New Potent Anticancer Agents
  作者：Romeo Romagnoli、Pier Giovanni Baraldi、Maria Kimatrai Salvador、Delia Preti、Mojgan Aghazadeh Tabrizi、Marcella Bassetto、Andrea Brancale、Ernest Hamel、Ignazio Castagliuolo、Roberta Bortolozzi、Giuseppe Basso、Giampietro Viola

  DOI：10.1021/jm400043d

  日期：2013.3.28

  Two new series of inhibitors of tubulin polymerization based on the 2-(alkoxycarbonyl)-3-(3',4',5'-trimethoxyanilino)benzo[b]thiophene and thieno[2,3-b]pyridine molecular skeletons were synthesized and evaluated for antiproliferative activity on a panel of cancer cell lines, inhibition of tubulin polymerization, cell cycle effects, and in vivo potency. Antiproliferative activity was strongly dependent on the position of the methyl group on the benzene portion of the benzo[b]thiophene nucleus, with the greatest activity observed when the methyl was located at the C-6 position. Also, in the smaller thieno[2,3-b]pyridine series, the introduction of the methyl group at the C-6 position resulted in improvement of antiproliferative activity to the nanomolar level. The most active compounds (4i and 4n) did not induce cell death in normal human lymphocytes, suggesting that the compounds may be selective against cancer cells. Compound 4i significantly inhibited in vivo the growth of a syngeneic hepatocellular carcinoma in Balb/c mice.
• US9238026B2
  申请人：——

  公开号：US9238026B2

  公开（公告）日：2016-01-19
• [EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TET2
  申请人：[en]NOVARTIS AG

  公开号：WO2023214325A1

  公开（公告）日：2023-11-09

  The present invention relates to novel pyrazolopyrimidine compounds that are TET2 inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by a TET2 inhibitor.